Usca Ria LLC maintained its position in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,890 shares of the medical instruments supplier’s stock at the end of the second quarter. Usca Ria LLC’s holdings in Becton, Dickinson and were worth $564,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Almanack Investment Partners LLC. purchased a new stake in Becton, Dickinson and in the first quarter worth about $105,000. Parkside Financial Bank & Trust grew its holdings in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 9 shares during the period. QCI Asset Management Inc. NY grew its holdings in Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after purchasing an additional 60 shares during the period. Financial Architects Inc grew its holdings in Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after purchasing an additional 54 shares during the period. Finally, Guardian Life Insurance Co. of America grew its holdings in Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 6 shares during the period. 87.12% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Becton, Dickinson and Company (BDX) Stake Held by Usca Ria LLC” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/25/becton-dickinson-and-company-bdx-stake-held-by-usca-ria-llc.html.

BDX has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, July 17th. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Cowen and Company restated a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Bank of America Corporation restated a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $200.93.

In other Becton, Dickinson and news, EVP Ribo Alberto Mas sold 7,463 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the sale, the executive vice president now owns 29,323 shares of the company’s stock, valued at approximately $5,905,945.43. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by insiders.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 193.06 on Monday. The stock has a market cap of $43.93 billion, a PE ratio of 55.91 and a beta of 1.06. The company has a 50-day moving average of $199.01 and a 200 day moving average of $191.58. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.35 EPS. On average, analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.51%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.